← All Allovir, INC filings

Allovir, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

ALVR
Allovir, INC
SCHEDULE: RTW Investments Discloses 5.7% Stake in Kalaris Therapeutics
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have reported a 5.7% beneficial ownership stake in Kalaris Therapeutics, Inc. as of December 31, 2025.
ALVR
Allovir, INC
SCHEDULE: Invus Group Affiliates Maintain 1.5% Stake in Kalaris Therapeutics
Invus Public Equities and its affiliated entities, including Invus Public Equities Advisors, Invus Global Management, Siren, and Raymond Debbane, continue to collectively hold a 1.5% beneficial ownership in Kalaris Therapeutics, Inc.
ALVR
Allovir, INC
SCHEDULE 13G/A: EcoR1 Capital Discloses 1.1% Passive Stake in Kalaris Therapeutics
EcoR1 Capital, LLC and affiliated entities have filed an amended Schedule 13G, reporting a 1.1% beneficial ownership stake in Kalaris Therapeutics, Inc. as of March 31, 2025.
ALVR
Allovir, INC
SCHEDULE 13G/A: Gilead Sciences Discloses 3.9% Stake in Newly Renamed Kalaris Therapeutics Following Merger
Gilead Sciences, Inc. has filed an amended Schedule 13G, disclosing a 3.9% beneficial ownership stake in Kalaris Therapeutics, Inc., which recently completed a merger and changed its name and ticker symbol.
ALVR
Allovir, INC
SCHEDULE 13G/A: EcoR1 Capital Discloses 8.1% Stake in Allovir, Inc. Following Reverse Stock Split
EcoR1 Capital, LLC and its affiliates have disclosed a beneficial ownership of 8.1% in Allovir, Inc.'s common stock as of December 31, 2024, following a recent 1-for-23 reverse stock split.